Dihexa mastery course
Unit 8 of 10

Safety & Side Effects

In the sources this course holds, dihexa taken as dihexa has no human safety dataset at all; the only controlled data…

The c-Met oncology signal and the missing safety data

In the sources this course holds, dihexa taken as dihexa has no human safety dataset at all; the only controlled data come from injections of its prodrug. The most important safety issue is not a reported side effect but a theoretical one: c-Met is a proto-oncogene, and a molecule that potentiates it systemically carries a mechanism-intrinsic cancer concern.

This unit sets out what is actually known, which is very little, features the oncology signal prominently, and closes on what the absence of any FDA-approved product means for anything anyone obtains. Education only, as always.

Key terms

The safety data gap


The c-Met oncology concern


The industry builds inhibitors, not potentiators


The broader theoretical risk map


Who should be most cautious


The grey-market quality problem